Uromigos-Kidney Cancer

The UromigosThe Uromigos | February 12, 2024
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Listen Now
The UromigosThe Uromigos | January 30, 2024
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
The UromigosThe Uromigos | January 30, 2024
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
The UromigosThe Uromigos | January 11, 2024
Cristina Suarez discusses the biggest RCC trials of 2023.
The UromigosThe Uromigos | January 12, 2024
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
The UromigosThe Uromigos | November 13, 2023
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
The UromigosThe Uromigos | October 30, 2023
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
The UromigosThe Uromigos | October 16, 2023
Dr. Toni Choueiri discusses progress in systemic therapy for papillary renal cell carcinoma, as well as personalized therapy.
The UromigosThe Uromigos | September 19, 2023
Dr. Celeste Simon discusses her career in translational science and kidney cancer at the University of Pennsylvania.
The UromigosThe Uromigos | September 20, 2023
Dr. Laurence Albiges discusses biomarker studies and new combinations and therapies presented at the KCRS23 meeting.
The UromigosThe Uromigos | September 19, 2023
Rachel Giles, MD, PhD, describes her patient data on adjuvant and first line treatments in renal cell carcinoma.
The UromigosThe Uromigos | July 25, 2023
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
The UromigosThe Uromigos | July 6, 2023
Bob Motzer, MD, joins the discussion on IPI/Nivo versus VEGF/PD1 to give his perspective on the recent debate from ASCO 2023.
The UromigosThe Uromigos | June 21, 2023
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
The UromigosThe Uromigos | August 1, 2023
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
The UromigosThe Uromigos | August 1, 2023
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
The UromigosThe Uromigos | August 1, 2023
Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer.
The UromigosThe Uromigos | August 1, 2023
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
The UromigosThe Uromigos | August 1, 2023
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
The UromigosThe Uromigos | August 1, 2023
A summary of the renal cancer session of the Conversations & Trending Topics in GU Cancers conference in the Canary Islands.
Advertisement
Advertisement